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Angiogenesis is a requirement for tumor growth and metastasis and occurs through several signalling 
palhways. One key palhway Ihal iniliales proliferalion and migration of endolhelial cells is signalling 
Ihrough lhe vascular endothelial growth factor receptor-2 (VEGFR-2),' Therefore, small molecules that 
block this signalling pathway through inhibition of the VEGFR tyrosine kinase activity could polentially 
inhibit angiogenesis and tumour growth. Recently works describing Ihienopyrimidines' and 
thienopyridine ureas' as inhibilors of VEGFR-2 have appeared in the literature. Here we presenl lhe 
synlhesis of new 1,3-diarylureas 2 starting by regioseleclive nucleophilic subslilulion of lhe 4-
chlorothieno[3,2-d]pyrimidine with 4-aminophenol lo obtain 4-(lhieno[3,2-d]pyridin-4-yloxy)aniline 1 
which reacls with diflerent arylisocyanales (Scheme). 
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The synlhesized compounds 2 were evalualed as polential VEGFR-2 tyrosine kinase inhibilors using 
AuloDock Vina as molecular docking software. The receptor X-ray 3-D structure was obtained from the 
Protein Data Sank: VEGFR2 (PDS: lYWN) and the estimaled inhibition conslanls (Ki) of lhe 
synthesised compounds were obtained. ln order lo validale lhe molecular docking approach, lhe 
respective co-crystallized ligand (LlF) and Sorafenib, a known drug that inhibil VEGFR-2, were docked 
to the kinase domain. The diflerence between the X-ray conformation and the predicted docked 
conformations of both ligands as well as the diflerence between estimated Ki (Sorafenib: 109 nM; LlF: 
7 nM) and experimental Ki (Sorafenib: 93 nM', LlF: 2 nMs) were negligible, validating the protein 
slructures for virtual screening wilh lhe synthesised compounds. Their polential use as fulure drugs 
was studied by applying lhe lipinski's Rule of Five analysis and ii was observed thal ali compounds 
respecled Ihis rule. The eslimated values of Ki were 180 nM for 2a, 214 nM for 2b and 66 nM for 2c, 
showing thal lhe presence of lhe nitrile group significantly lowers the Ki vai ue when compared lo lhe 
melhoxy group of 2b. ln this series compound 2c is the most promising one. 
Moreover, the docking pose of the compounds wilh lhe besl docking score was analyzed in order to 
undersland the key inleractions belween the compounds and lhe VEGFR-2 kinase domain slruclure. 
Acknowledgments: FCT (Portugal) and COMPETElQREN/EU for financial support Ihrough research 
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The development af anticancer drugs inhibiting angiogenesis has been an area of extensive research 
in the past decade. Angiogenesis is a requirement for tumor growth and metastasis and occurs 
through several signalling pathways. One key pathway that initiates prolileration and migration 01 
endothelial cells is signalling through the vascular endothelial growth lactor receptor-2 (VEGFR-2).' 
Therelore , small molecules Ihal block Ihis signalling palhway Ihrough inhibilion 01 VEGFR-2 tyrasine 
kinase aclivily could potentially inhibit angiogenesis and tumor growth. Recently works describing 
Ihienopyrimidines' and thienopyridine 1,3-diarylureas' as VEGFR-2 inhibitors have emerged in the 
literature. Here we present the synthesis 01 new 1-aryl-3-(4-(7-methylthieno[3,2-d]pyrimidin-4-
yloxy)phenyl)ureas 2 in high yields by reaction 01 4-[(7-methylthieno[3,2-d]pyridin-4-yl)oxy]aniline 1 
with arylisocyanates. The lormer was prepared by regioselective nucleophilic substitution 01 4-chloro-
7-melhyllhieno[3,2-d]pyrimidine wilh 4-aminophenol (Scheme). 
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Compounds 2 were evaluated as potential VEGFR-2 tyrosine kinase inhibitors using AuloDock Vina as 
molecular docking software. The receptor X-ray 3-D structure was oblained Iram lhe Prolein Dala 
Sank: VEGFR2 (PDS: 1YWN) and the estimated inhibition constanls (Ki) 01 the synlhesised 
compounds were obtained. ln order lo validale the molecular docking approach, the respective co-
crystallized ligand (LlF) and Sorafenib, a known drug that inhibit VEGFR-2, were docked lo the kinase 
domain. The difference belween the X-ray conlormation and lhe predicted docked conlormations 01 
both ligands as well as the difference between estimated Ki (Soralenib: 109 nM; LlF: 7 nM) and 
experimenlal Ki (Soralenib: 93 nM' , LlF : 2 nMs) were negligible, validaling lhe protein slruclures lar 
virtual screening wilh the synthesised compounds. 
The polenlial use 01 compounds 2 as lulure drugs was sludied by applying lhe Lipinski 's Rule 01 Five 
analysis and it was observed thal ali the compounds respecled Ihis rule. The estimaled values 01 Ki 
were 109 nM lar 2a, 354 nM lar 2b and 47 nM for 2c, showing thal lhe presence 01 lhe nilrile group 
makes this compound the most promising of this series. 
Moreover, the docking pose 01 lhe compounds wilh lhe besl docking score was analyzed in arder lo 
undersland lhe key interactions belween lhe compounds and the VEGFR-2 kinase domain slructure. 
Acknowledgments: FCT (Portugal) and COMPETE/QREN/EU lar financial support Ihrough research 
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